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Unresectable hepatocellular carcinomas (HCC) are currently treated with local injections of 
chemotherapeutics or radioactive particles during transarterial liver catheterization, aimed at 
increasing tumor drug concentrations, while limiting systemic toxicity. As optimal treatment 
conditions are still unknown, we explored the added value of computational models to optimize 
targeted drug delivery. 
A patient-specific 3D hepatic arterial geometry was obtained from micro-CT data and meshed using 
8.9 million volume elements. Computational fluid dynamics calculations simulated both the blood 
flow (continuous shear-thinning fluid phase) and drug transport (discrete phase) in the liver. 
Boundary conditions included a velocity inlet of 0.155 m/s at the hepatic artery, an outlet flow 
distribution (Murray’s law) and a uniform surface injection of 104 particles. The impact of relevant 
parameters on the particle distribution was analyzed using a sensitivity study. 
Results showed that the cross-sectional injection location has a large impact on the particle 
distribution. A good choice of this parameter may allow targeting specific outlets or tumors. Other 
parameters having a significant impact on the particle distribution, are the injection plane 
(proximal/distal catheter position), the particle density (1600-3600 kg/m³), and the particle diameter 
(40-100 µm), leading to changes in the outlet-specific number of exiting particles up to ± 64%, 61%, 
and 79%, respectively.  
 
These preliminary results indicate the potential of patient-specific computational models to optimize 
targeted drug delivery for liver cancer [1]. Future work will focus on validating and testing the model 
in a cohort of patients that received transarterial therapy. 
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